医学
支气管肺发育不良
重症监护医学
心理干预
儿科
病理生理学
怀孕
内科学
胎龄
遗传学
生物
精神科
作者
Erica W. Mandell,Panagiotis Kratimenos,Steven H. Abman,Robin H. Steinhorn
标识
DOI:10.1016/j.clp.2019.02.011
摘要
Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI